Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Vakif Gureba Cad., Capa Kampusu Sehremini, Fatih, 34093, Istanbul, Turkey.
Department of Neurology, Bagcilar Training and Research Hospital, University of Health Sciences, 34200, Istanbul, Turkey.
Alzheimers Res Ther. 2023 Feb 28;15(1):43. doi: 10.1186/s13195-023-01187-9.
In preclinical Alzheimer's disease, it is unclear why some individuals with amyloid pathologic change are asymptomatic (stage 1), whereas others experience subjective cognitive decline (SCD, stage 2). Here, we examined the association of stage 1 vs. stage 2 with structural brain reserve in memory-related brain regions.
We tested whether the volumes of hippocampal subfields and parahippocampal regions were larger in individuals at stage 1 compared to asymptomatic amyloid-negative older adults (healthy controls, HCs). We also tested whether individuals with stage 2 would show the opposite pattern, namely smaller brain volumes than in amyloid-negative individuals with SCD. Participants with cerebrospinal fluid (CSF) biomarker data and bilateral volumetric MRI data from the observational, multi-centric DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) study were included. The sample comprised 95 amyloid-negative and 26 amyloid-positive asymptomatic participants as well as 104 amyloid-negative and 47 amyloid-positive individuals with SCD. Volumes were based on high-resolution T2-weighted images and automatic segmentation with manual correction according to a recently established high-resolution segmentation protocol.
In asymptomatic individuals, brain volumes of hippocampal subfields and of the parahippocampal cortex were numerically larger in stage 1 compared to HCs, whereas the opposite was the case in individuals with SCD. MANOVAs with volumes as dependent data and age, sex, years of education, and DELCODE site as covariates showed a significant interaction between diagnosis (asymptomatic versus SCD) and amyloid status (Aß42/40 negative versus positive) for hippocampal subfields. Post hoc paired comparisons taking into account the same covariates showed that dentate gyrus and CA1 volumes in SCD were significantly smaller in amyloid-positive than negative individuals. In contrast, CA1 volumes were significantly (p = 0.014) larger in stage 1 compared with HCs.
These data indicate that HCs and stages 1 and 2 do not correspond to linear brain volume reduction. Instead, stage 1 is associated with larger than expected volumes of hippocampal subfields in the face of amyloid pathology. This indicates a brain reserve mechanism in stage 1 that enables individuals with amyloid pathologic change to be cognitively normal and asymptomatic without subjective cognitive decline.
在临床前阿尔茨海默病中,尚不清楚为什么有些有淀粉样蛋白病理改变的个体是无症状的(阶段 1),而另一些则经历主观认知下降(SCD,阶段 2)。在这里,我们研究了阶段 1 与阶段 2 与记忆相关脑区的结构性脑储备之间的关联。
我们测试了与无症状淀粉样蛋白阴性的老年个体(健康对照组,HCs)相比,处于阶段 1 的个体的海马亚区和海马旁区体积是否更大。我们还测试了处于阶段 2 的个体是否会表现出相反的模式,即与有 SCD 的无淀粉样蛋白个体相比,脑体积更小。参与者有脑脊液(CSF)生物标志物数据和来自观察性、多中心 DZNE-纵向认知障碍和痴呆研究(DELCODE)的双侧容积 MRI 数据。该样本包括 95 名无淀粉样蛋白阴性和 26 名淀粉样蛋白阳性无症状参与者以及 104 名无淀粉样蛋白阴性和 47 名淀粉样蛋白阳性有 SCD 的个体。体积基于高分辨率 T2 加权图像,并根据最近建立的高分辨率分割协议进行自动分割和手动校正。
在无症状个体中,与 HCs 相比,阶段 1 个体的海马亚区和海马旁皮质的脑体积在数值上更大,而 SCD 个体则相反。以体积为因变量数据的 MANOVA 分析,并以年龄、性别、受教育年限和 DELCODE 地点为协变量,显示诊断(无症状与 SCD)和淀粉样蛋白状态(Aß42/40 阴性与阳性)之间存在显著交互作用。考虑到相同协变量的事后配对比较表明,SCD 中的齿状回和 CA1 体积在淀粉样蛋白阳性个体中明显小于阴性个体。相比之下,与 HCs 相比,阶段 1 的 CA1 体积明显更大(p=0.014)。
这些数据表明,HCs 以及阶段 1 和 2 并不对应于线性脑体积减少。相反,阶段 1 与淀粉样蛋白病理相关的海马亚区体积大于预期。这表明阶段 1 存在一种脑储备机制,使有淀粉样蛋白病理改变的个体能够在没有主观认知下降的情况下保持认知正常和无症状。